CAR-T therapy delivered significant clinical improvements in adults with stiff person syndrome (SPS) in the pivotal ...
EMERYVILLE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune ...
MedPage Today on MSN
Stiff Person Syndrome Patients Regain Mobility After Single-Dose Cell Therapy
CAR-T therapy shows promise in clinical trial ...
Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies -- outcomes not previously observed in SPS ...
Good morning, and welcome to the Kyverna Therapeutics Investor Conference Call. [Operator Instructions] Please note that this call is being recorded. I would now like to introduce Jessica Serra, Head ...
Shares of Kyverna Therapeutics KYTX surged 23.2% on Monday after the company reported positive top-line data from a registrational mid-stage study of its investigational candidate, mivocabtagene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results